PT-141 vs semaglutide: two brain targets

Search engines keep putting PT-141 and semaglutide on the same page because both are peptide drugs, both carry a regulator-approved product, and both do their main work on receptors inside the brain rather than in the tissue you are trying to change. That is the whole overlap. One is licensed for low sexual desire in premenopausal women, the other for weight, blood sugar and cardiovascular risk. No trial has ever compared them, and nothing about either drug makes it a stand-in for the other.

What each one is licensed to do

Bremelanotide, sold in the United States as Vyleesi, is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), meaning low sexual desire that causes marked distress and is not explained by another medical or psychiatric condition, a relationship problem, or another drug^[1]. The label carries two explicit limitations of use: it is not indicated for HSDD in postmenopausal women or in men, and it is not indicated to enhance sexual performance^[1]. Initial US approval was 2019^[1].

Semaglutide's US label under the Wegovy brand covers reduction of major adverse cardiovascular events in adults with established cardiovascular disease plus obesity or overweight, reduction and long-term maintenance of excess body weight in adults and in patients aged 12 and over with obesity, and, under accelerated approval, noncirrhotic MASH with stage F2 to F3 fibrosis^[2]. In Europe the same molecule holds a central marketing authorisation from the European Medicines Agency^[3]. Bremelanotide has no equivalent European authorisation. Our PT-141 regulation section tracks where that leaves readers outside the United States.

The dopamine framing gets the receptor wrong

A common shorthand in podcasts and clinic marketing is that Vyleesi works on dopamine pathways. The prescribing information says something narrower. Bremelanotide is described as a melanocortin receptor agonist that nonselectively activates several receptor subtypes, in this order of potency: MC1R, MC4R, MC3R, MC5R, MC2R, with binding at MC1R and MC4R the most relevant at therapeutic doses^[1]. The same section then states plainly that the mechanism by which the drug improves HSDD in women is unknown^[1]. The word dopamine does not appear anywhere in the label.

There is a real dopamine story, but it sits one step downstream and comes from animal work. A 2022 review in CNS Spectrums sets out the neurobiology: MC4R is predominantly expressed in the medial preoptic area of the hypothalamus, and animal studies suggest bremelanotide may affect female sexual desire by activating presynaptic MC4Rs on neurons there, which increases dopamine release^[4]. That is a proposed chain of events in rodents rather than a receptor the drug binds. The author list also carries affiliations at AMAG Pharmaceuticals and Palatin Technologies, the two companies behind the product^[4].

The confusion is easier to explain once you look at the other approved HSDD drug. Flibanserin (Addyi) does bind monoamine receptors directly: high affinity as a 5-HT1A agonist and 5-HT2A antagonist, with moderate antagonist activity at 5-HT2B, 5-HT2C and the dopamine D4 receptor^[5]. Its label also says the mechanism in HSDD is not known^[5]. Two approved drugs, one indication, and neither manufacturer claims to know why the treatment works.

Acting centrally is a weak thing to have in common

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1 that binds and activates the GLP-1 receptor^[2]. Its brain action appears on the label as well. GLP-1 receptors are present in several brain areas involved in appetite regulation, and in animal work semaglutide distributed to and activated neurons in brain regions that regulate food intake^[2]. So both drugs reach brain receptors. They reach different receptor families, in different circuits, to change different behaviours. Grouping them as centrally acting peptides describes where they act and tells you nothing useful about what happens next.

The trial evidence is not on the same scale

Bremelanotide's approval rests on RECONNECT, two identically designed double-blind, placebo-controlled trials that randomised 1,267 premenopausal women with HSDD to 1.75 mg subcutaneously as needed or placebo for 24 weeks^[6]. Against placebo, the integrated increase in the Female Sexual Function Index desire domain was 0.35 (P<.001) on a scale that runs from 1.2 to 6.0, and the integrated reduction in desire-related distress was 0.33 (P<.001) on a 0 to 4 scale^[6][1]. Both results are statistically significant and small. Nausea hit 40% of treated patients, and 18% stopped because of an adverse reaction against 2% on placebo^[1].

The semaglutide evidence base is a different size of thing. STEP 1 randomised 1,961 adults without diabetes and reported a mean body-weight change of -14.9% at 68 weeks against -2.4% on placebo^[7]. SELECT followed 17,604 patients with cardiovascular disease and overweight or obesity but no diabetes for a mean of 39.8 months, and found a primary cardiovascular event in 6.5% on semaglutide against 8.0% on placebo (hazard ratio 0.80, 95% CI 0.72 to 0.90, P<0.001)^[8]. A cardiovascular event endpoint measured in 17,604 people and a two-question desire score measured in 1,267 people are not comparable quantities.

What this comparison is not

No head-to-head trial of PT-141 against semaglutide exists, and there is no clinical reason to run one. They are not alternatives, they do not treat overlapping conditions, and choosing between them is not a decision any patient faces. Both are prescription medicines: Vyleesi is dispensed by prescription in the US, and semaglutide is prescription-only everywhere we cover^[1][2]. PT-141 in particular is sold heavily by online research-chemical vendors under the original Palatin code name, outside any regulated supply chain. We do not link vendors, we do not publish dosing instructions, and the numbers above are label and trial figures rather than a protocol. Our semaglutide regulation section sets out the country picture for that side of the comparison.

What we don't yet know

The bremelanotide label is unusually candid about its own gaps. The duration of efficacy after each dose is unknown, the optimal window for administration has not been fully characterised, and resolution of focal hyperpigmentation was not confirmed in all patients after stopping^[1]. Whether the drug does anything for men was still being posed as an open question in the literature in 2026^[9], and the label is explicit that it is not indicated for men^[1]. On the semaglutide side, the exact mechanism of cardiovascular risk reduction has not been established, and the MASH indication runs under accelerated approval pending a confirmatory trial^[2]. This article is educational and is not medical advice. Anything you decide about either drug belongs with a clinician who knows your history.